Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04661072

Enrollment

300

Registered

2020-12-09

Start date

2021-07-14

Completion date

2027-08-01

Last updated

2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Uterine Anomaly

Keywords

Cancer associations, Environmental factors

Brief summary

The purpose of this research study is to learn more about the health outcomes associated with congenital uterine anomalies (CUAs), and the possible environmental and genetic causes of the condition. The researchers plan to investigate whether any cancer associations (with breast, renal, ovarian, vaginal and uterine cancers) exist in females with CUAs. The investigator will also investigate any environmental and genetic factors that may be responsible for causing CUAs.

Detailed description

Aim 1: To identify female subjects diagnosed with a Congenital Uterine Anomaly (CUA) receiving care at Yale New Haven Health. Aim 2: Identify (i) the prevalence of renal, breast, ovarian, uterine and vaginal cancers associated with CUAs, and (ii) the association of environmental factors, via a survey obtained by phone, email or interview. Aim 3: Conduct genetic evaluation of the index subjects, parents, sister(s) (as feasible), and female offspring to identify potential causes and patterns of inheritance using whole exome sequencing (WES) and microarray. Following informed consent, blood will be collected for genetic evaluation. DNA will be extracted from EDTA-blood and analyzed using an integrated approach of microarray for copy number variations (CNV), and Whole Exome Sequencing (WES) for Single Nucleotide Variation (SNV). Undertaking review of the medical records will identify the cohort of patients we wish to survey to then ascertain further information regarding their CUA diagnosis and other related details. The information to be elicited from the survey are outlined in the attached survey questions. Key associations we seek to investigate include (1) the type and prevalence of renal, breast, ovarian, uterine and vaginal cancers among patients with Mullerian Anomaly, and (2) identifying potential in-utero exposure to particular environmental agents in patients with CUAs. Review of the medical records will enable us to undertake this first key step of establishing a cohort of subjects with MA and an initial data set related to their specific health information. We anticipate further investigations may build upon this initial data set, both with the cohort established, and more broadly with collaborators and additional national and international cohorts of patients with MA.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

13 Years to No maximum

Healthy volunteers

Inclusion criteria

* females * age: 13 or older * encounters limited to: Yale New Haven Hospital, Bridgeport Hospital, Greenwich Hospital and Lawrence+ Memorial Hospital. * diagnosis of any variation of CUA

Exclusion criteria

* who will decline to participate in a study upon contact * non-English speaking except Spanish speaking * unable to participate in consent or assent process due to mental disability

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of breast cancer in women with CUA's compared to women without CUA's	6-months	Prevalence of breast cancer in women with CUA's compared to women without CUA's will be measured
Prevalence of ovarian cancer in women with CUA's compared to women without CUA's	6-months	Prevalence of ovarian cancer in women with CUA's compared to women without CUA's will be measured
Prevalence of uterine cancer in women with CUA's compared to women without CUA's	6-months	Prevalence of uterine cancer in women with CUA's compared to women without CUA's will be measured
Prevalence of cervical cancer in women with CUA's compared to women without CUA's	6 month	Prevalence of cervical cancer in women with CUA's compared to women without CUA's will be measured
Prevalence of vaginal cancer in women with CUA's compared to women without CUA's	6 month	Prevalence of vaginal cancer in women with CUA's compared to women without CUA's will be measured
Prevalence of renal cancer in women with CUA's compared to women without CUA's	6 month	Prevalence of renal cancer in women with CUA's compared to women without CUA's will be measured

Secondary

Measure	Time frame	Description
Whole exome sequencing (WES) and microarray	24 months	WES and microarray will be conducted in subjects with CUAs. The discovery of possible causative genes would be measured using yes/no outcome variable.

Countries

United States

Contacts

CONTACTAlla Vash-Margita, MD

alla.vash-margita@yale.edu203-785-4010

CONTACTMiranda Margetts, PhD

miranda.margetts@yale.edu

PRINCIPAL_INVESTIGATORAlla Vash-Margita, MD

Yale University

PRINCIPAL_INVESTIGATOREmanuele Pelosi, MD